Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer
This study is a single center, phase II study, to evaluate the effectiveness and safety of POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the neoadjuvant therapy for patients with advanced/metastatic gastric cancer.
Gastric Cancer
DRUG: paclitaxel ,oxaliplatin,fluorouracil
Pathological complete and subtotal regression (TRG1a/b by Becker), Pathological complete and subtotal regression (TRG1a/b by Becker). TRG1a/b is defined as \< 10% residual tumor per tumor bed based on evaluation of the resected esophagogastric specimen in the primary by a pathologist., after 4 cycles (each cycle is 14 days) + surgery; i.e. after 12 weeks in total
This study is a single center, phase II study, to evaluate the effectiveness and safety of POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the neoadjuvant therapy for patients with advanced/metastatic gastric cancer.